Xiuqin Zhang, MD., Ph.D.

Director, Pathology Core,

Director, Non-human Primate Research Center

Biography

Dr. Xiuqin Zhang is a principal investigator in the College of Future Technology, Peking University, China. Her research interests are the establishment of metabolic and cardiovascular disease models in non-human primates; The pathogenesis of obesity, NAFLD, and type 2 diabetes in primate and rodent models; Preclinical study using primate models. She has published nearly 40 scientific papers in peer-reviewed journals including Circulation, Diabetes, Nature Communications, etc.

Courses

n Experimental Pathology (2 credits)

Education

n MS 1995 Clinical Pathology, China Medical University (Supervisor: Prof. Zongxuan Li)

n Ph. D.  2002 Medical Science, Kumamoto University, School of Medicine, Japan (Supervisor: Prof. Toshio Suda)

Experience

n 1995. 7-1996. 6, Resident, Department of Pathology, Fuwai hospital, Beijing, China

n 1996. 7-1997. 3, Visiting Scientist, Department of Tumor Biology, Kumamoto University, School of Medicine, Japan

n 1997. 4-1998. 3, Research Faculty, Department of Cell Differentiation, Kumamoto University, School of Medicine, Japan

n 2002. 4-2006. 2, Research Associate, Department of Molecular Biology and Pharmacology, Washington University School of Medicine (Advisor: Prof. David M. Ornitz)

n 2006. 3-2013. 8, Associate Investigator and Co-principle Investigator, Non-human Primate Research Center, Institute of Molecular Medicine, Peking University, Beijing, China

n 2013. 9-2021. 3, Principal Investigator, Non-human Primate Research Center, Institute of Molecular Medicine, Peking University, Beijing, China

n 2021. 4-present, Principal Investigator, Non-human Primate Research Center, Institute of Molecular Medicine, College of Future Technology, Peking University, Beijing, China

Projects:

n 2019.11 – 2024.10, Principal Investigator, National Key R&D Program of China (2018YFA0801405)

Title: Establishment and mechanistic study of primate models of metabolic and cardiovascular diseases (RMB 8,640,000)

n 2020.01 – 2023.12, Principal Investigator, National Natural Science Foundation of China (No. 81970690)

Title: Mechanistic study of β cell specific RIPK1 knockout protects high-fat diet induced glucose intolerance in mice (RMB 550,000)

Representative publications:

1. Zhang X*, Li D*, Sun R*, Hu X*, Song Z*, Ni X, Zhu H, Guo T*, Qin C*, Xiao RP*. sRAGE alleviates SARS-CoV-2-induced pneumonia in hamster. Signal Transduct Target Ther. 2022 Feb 2;7(1):36. doi: 10.1038/s41392-022-00883-6.

2. Zhu T*, Lei M*, Wang Z, Zhang R, Zhang Y, Jin W, Yu C, Huang CL, Liu D, Zheng W, Liu Y, Quan X, Kong L, Liang S, Zhang X*. A Comparative Study of Systolic and Diastolic Mechanical Synchrony in Canine, Primate, and Healthy and Failing Human Hearts. Front Cardiovasc Med. 2021 Oct 28;8:750067.

3. Wang J*, Chu Y, Li J, Zeng F, Wu M, Wang T, Sun L, Chen Q, Wang P, Zhang X*, Zeng F*. Development of a prediction model with serum tumor markers to assess tumor metastasis in lung cancer. Cancer Med. 2020 Aug;9(15):5436-5445

4. Wang C*, Xiao Y*, Wang J, Hou N, Cui W, Hu X, Zeng F, Yuan Y, Ma D, Sun X, Zhang Y, Zheng W, Liu Y, Shang H, Chen L, Xiao RP*, Zhang X*. Dynamic Changes in Insulin and Glucagon During Disease Progression in Rhesus Monkeys with Obesity-Related Type 2 Diabetes Mellitus. Diabetes Obes Metab. 21:1111-1120, 2019. 2019 May;21(5):1111-1120. doi: 10.1111/dom.

5. Sun X*, Wang J*, Yao X*, Zheng W, Mao Y, Lan T, Wang L, Sun Y, Zhang X, Zhao Q, Zhao J, Xiao RP, Zhang X*, Ji G*, Rao Y*. A chemical approach for global protein knockdown from mice to non-human primates. Cell Discov. 2019, 5:10. doi: 10.1038/s41421-018-0079-1. eCollection, 2019.

6. Zeng F*, Wen W*, Cui W, Zheng W, Liu Y, Sun X, Hou N, Ma D, Yuan Y, Shi H, Wang Z, Li Z, Xiao Y, Wang C, Li Y, Shang H, Li CY, Wang J, Zhang Y, Xiao R-P*, Zhang X*. Central role of RIPK1-VDAC1 pathway on cardiac impairment in a non-human primate model of rheumatoid arthritis. J Mol Cell Cardiol. 125:50-60, 2018.

7. Zheng W*, Liu Y*, Shang H, Zhang Y, Ma D, Hou N, Wang J, Sun X, Peng Y, Pan L, Wang Z, Tang X, Xiao R‑P, Zhang X*. Characterization of spontaneously developed non-alcoholic fatty liver disease in aged rhesus monkeys. Diabetol Metab Syndr. 10:68, 2018.

8. Xiao Y*, Wang C*, Chen JY, Lu F, Wang J, Hou N, Hu X, Zeng F, Ma D, Sun X, Ding Y, Zhang Y, Zheng W, Liu Y, Shang H, Zhu W, Han C, Zhang Y, Ouyang K, Chen L, Chen J, Xiao RP, Li CY*, Zhang X*. Deficiency of PRKD2 triggers hyperinsulinemia and metabolic disorders. Nat Commun. 9:2015, 2018.

9. Zeng F*, Chen X*, Cui W*, Wen W, Lu F, Sun X, Ma D, Yuan Y, Li Z, Hou N, Zhao H, Bi X, Zhao J, Zhou J, Zhang Y, Xiao RP, Cai J*, Zhang X*. RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca2+ Uptake and Promotes Colorectal Oncogenesis. Cancer Res. 78:2876-2885, 2018.

10. Zhang Y*, Zheng W, Liu Y, Wang J, Peng Y, Shang H, Hou N, Hu X, Ding Y, Xiao Y, Wang C, Zeng F, Mao J, Zhang J, Ma D, Sun X, Li C, Xiao RP*, Zhang X*. Eplerenone restores 24-h blood pressure circadian rhythm and reduces advanced glycation end-products in rhesus macaques with spontaneous hypertensive metabolic syndrome. Sci Rep. 6:23957, 2016.